Due to the high medical risks of using live stem cells, they have been highly regulated. Currently, the only legal way to use live stem cells is if they have been derived from the patient themselves or are not manipulated in any way and used as a tissue transplant. These current methods of using live stem cells have major shortcomings beyond the health risk. First, any tissue that is used as a transplant is limited in its application by only being able to be applied to similar tissue (placenta membranes may only be used on similar skin type tissues). Second, any self-derived stem cells are subject to degradation due to aging. At the age of 40, a person’s stem cells begin to lose effectiveness. By the age of 60, the age of most patients needing stem cell treatments, the stem cells are barely effective, if at all.
We combat this by using a placenta from new birth and extracting the mesenchymal stem cells. This allows us to use the newest and most potent stem cells possible. We then screen and culture them in a lab to control the safety and efficacy of the cells. We then immerse them in the appropriate medium which allows them to secrete exosomes with consistent and high quantities of regenerative factors. Finally, we extract the exosomes and analyze them through batch testing at which point they are made available for research purposes.
WHY USE UMBILICAL CORD MSC DERIVED EXOSOMES
The use of regenerative medicine products such as BMA, PRP, Amnio, Stem Cells, and Exosomes have skyrocketed over the last decade. While some have reported great outcomes others have reported no effectiveness and in worse cases, harm has come to individuals through autoimmune responses, viruses, and tumors. Dynacord MSC Exosomes are created in a controlled environment achieving consistent product composition through different batches and different donors. They are rigorously tested through the same batch of safety testing as used in the pharmaceutical industry.